Abbott received approval for an expanded indication for Humira that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA). Humira is also approved in the U.S. for use in moderate to severe rheumatoid arthritis (RA) and active ankylosing spondylitis (AS). PsA is a chronic disease that combines symptoms of arthritis, including joint pain and inflammation, and those of psoriatic skin disease, such as painful, raised red lesions c...